Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell lung cancer: a multi-tumour, multi.institutional Phase II study

Schöffski, P; Besse, B; Gauler, T; M J A, de Jonge; Scambia, G; Santoro, A; Davite, C; M G, Jannuzzo; Petroccione, A; J P, Delord

Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell lung cancer: a multi-tumour, multi.institutional Phase II study / Schöffski P; Besse B; Gauler T; de Jonge M J A; Scambia G; Santoro A; Davite C; Jannuzzo M G; Petroccione A; Delord J P. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 26:3(2014), pp. 598-607.

Titolo:	Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell lung cancer: a multi-tumour, multi.institutional Phase II study
Autori:	Schöffski P Besse B Gauler T de Jonge M J A Scambia G SANTORO, Armando Davite C Jannuzzo M G Petroccione A Delord J P mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2014
Rivista:	ANNALS OF ONCOLOGY
Handle:	http://hdl.handle.net/11699/8804
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11699/8804

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: